Prediction of PIK3CA mutations from cancer gene expression data

**Abstract**

Breast cancers with PIK3CA mutations can be treated with PIK3CA inhibitors in hormone receptor-positive HER2 negative subtypes. We applied a supervised elastic net penalized logistic regression model to predict PIK3CA mutations from gene expression data. This regression approach was applied to predict modeling using the TCGA pan-cancer dataset. Approximately 10,845 cases were available for PIK3CA mutation and mRNA expression data. In 10-fold cross-validation, the model with = 0.01 and = 1.0 (Ridge regression) showed the best performance, in terms of area under the receiver operating characteristic (AUROC). The final model was developed with selected hyper-parameters using the entire train-set. The train-set AUROC was 0.93, and the test-set AUROC was 0.84. The area under the precision-recall (AUPR) of the train-set was 0.66, and the test-set AUPR was 0.39. Cancer types were the most important predictors. Both IGFR1R and the phosphatase and tensin homolog (PTEN) were the most significant genes in gene expression predictors. Our study suggests that predicting genomic alterations using gene expression data is possible, with good outcomes.

# Introduction

Targeted therapy has become a standard treatment for many cancer patients, however the approach requires a test for a specific cancer genomic alteration, to treat patients. Several direct genomic alteration tests have been developed and proven for their clinical utility to treat patients.

Machine learning approaches can be applied to detect genomic alterations. Machine learning algorithms can build prediction models from a large number of predictors, such as radiomic features [1], pathology images [2], or gene expression data [3]. Because most direct genomic tests are more specific and sensitive than predictive models, machine learning approaches may have limited roles in clinical practice, however, machine learning approaches are ideal when direct tests are unavailable or fail.

RAS pathway activation predictions have been performed using gene expression data [5]. Authors used data from The Cancer Genome Atlas (TCGA), with a supervised elastic net penalized logistic regression classifier, with stochastic gradient descent. Their model performance was 84% with an area under the receiver operating characteristic (AUROC) curve, and 63% with an area under the precision-recall (AUPR) curve. Importantly, these authors suggested their approach could be applied to other genomic alterations.

Breast cancer expressing PIK3CA mutations can be treated using PIK3CA inhibitors, in hormone receptor-positive HER2 negative subtypes [6]. The PIK3CA mutation is the second most common driver mutation after TP53, and is most frequently detected in endometrial carcinoma (45%), followed by breast invasive carcinoma (24%), cervical squamous cell carcinoma, endo-cervical adenocarcinoma (20%) and colon adenocarcinoma (16%).

PIK3CA encodes the p110 catalytic subunit of phosphatidylinositol 3′-kinase (PI3K). PI3K is a protein kinase that phosphorylates phosphatidylinositol 4,5-biphosphate (PIP2) to generate phosphatidylinositol 3,4,5-triphosphate (PIP3). The phosphatase and tensin homolog (PTEN) converts PIP2 to PIP3 in contrast to PI3K. PIP3 is a second messenger that activates protein kinase B (AKT), which is a serine/threonine-specific protein kinase. AKT inhibits apoptosis and promotes cell proliferation [7].

We applied a supervised elastic net penalized logistic regression model to predict PIK3CA mutations. We wanted to ascertain whether this prediction model approach could be applied not only to RAS pathway activation, but also to PIK3CA mutation predictions across several cancer types.

# Materials and methods

## Dataset

We used the TCGA pan-cancer dataset. TCGA archives the following; exome sequencing, gene expression, DNA methylation, protein expression, and clinical data from > 10,000 cancer samples across 33 common cancer types. The TCGA dataset is publically available. PIK3CA mutation data was extracted using cgdsr rpackage [8]. Gene expression data was downloaded from the National Cancer Institute (NCI)’s Genomic Data Commons (GDC) website. This archives data for TCGA (<https://gdc.cancer.gov/about-data/publications/pancanatlas>). Gene expression in the TCGA pan-cancer dataset is batch-corrected with normalization.

The target variable was PIK3CA mutation status. PIK3CA status was considered positive when the case had the following PIK3CA variants, which were the target variants of the Therascreen PIK3CA RGQ PCR Kit; C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y. This kit was approved as a companion diagnostics test to treat with PIK3CA inhibitor by the United States Food and Drug Administration. We split three-quarters of the dataset into the train-set and one quarter into the test-set.

## Modeling process

To narrow down potential predictors, genes with a large median absolute deviation (> third-quartiles) were selected. Thirty three cancer type dummy variables were included in predictor variables. Yeo-Johnson transformation was performed to correct skewness. Centering and scaling were also performed. All preprocessing was performed using the recipe r package [9]. Penalized logistic regression was applied to prediction modeling. Ten-fold cross-validation with targe variable stratification was performed over the hyper-parameter grid: {, , , , , }, {0.0, 0.25, 0.5, 0.75}. Lambda (λ) is a penalty scaling parameter and (α) alpha is a mixing parameter of penalty function () [10].

## Accessing model performance

Model performance was evaluated using AUROC and AUPR curve approaches. The AUPR approach is more informative than AUROC for imbalanced datasets [11]. The modeling process and accessing model performance were performed with the tidymodels rpackage [12].

# Results

## Dataset summary

10,845 cases were available for both PIK3CA mutation and mRNA expression data. 5,128 out of 20,502 genes were included in the modeling process, after filtering for median absolute deviation, as described in the modeling process method. The prevalence rate for PIK3CA was 0.11 in all cases. The PIK3CA prevalence rate in each cancer type varied. The median prevalence rate of PIK3CA for each cancer type was 0.03 (range 0–0.33) (Figure 1).

## Selecting model and performance estimations

For 10-fold cross-validation, the model with = 0.01 and = 1.0 (Ridge regression) showed the best performance in terms of AUROC. The final model was trained with the selected hyper-parameters with the entire train-set. The train-set AUROC was 0.93 and the test-set AUROC was 0.84. The AUPR of the train-set was 0.66 and the test-set AUPR was 0.39 (Figure 2A).

## Performance of each cancer type

Because PIK3CA mutation prevalence varied across cancer types, the performance of each cancer type was investigated. The AUROC and AUPR were positively correlated between the train-sets and test-sets in cancer type sub-analysis (Figure 2B). The AUPR was high in cancer types with high PIK3CA mutation rates such as colon, breast and uterus cancer types. The AUROC did not correlate with PIK3CA mutation rates of each cancer type (Figure 2C).

## Important predictors

The top 30 important predictors are shown (Figure 3). The coefficient is the parameter of the predictor which represents the effect of the predictor on prediction. IGF1R mRNA expression was the strongest negative predictor, and PTEN was the strongest positive predictor. Both IGFR1R and PTEN are key players in the tyrosine kinase pathway. The cancer types were important predictors. Some cancer types including uterine carcinosarcoma (UCS), bladder urothelial carcinoma (BLCA), pancreatic adenocarcinoma (PAAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) were the strongest predictors.

# Discussion

Our model showed good performance in predicting PIK3CA mutations in various cancer types. Our data suggested that the supervised elastic net penalized logistic regression model could be applied not only to the RAS activation pathway, but also to other genomic alterations. Both the RAS activation pathway and PIK3CA mutations are key, common cancer genomic alterations. When mutated, they exert significant effect on gene expression in cells. However, the supervised elastic net penalized logistic regression model cannot be generalized or applied to other genomic alterations. It might be a challenging prediction of genomic alterations that are infrequent or have a weak effect on gene expression.

Prediction modeling from the TCGA pan-cancer dataset can be limiting in terms of data preprocessing. The gene expression data is processed by between-sample normalization to remove batch effects. If the model has been trained from between-sample normalization, a new sample cannot be exactly preprocessed with normalization which was done on trainset. A model based on gene expression from the TCGA pan-cancer dataset is limited in terms of data preprocessing. It is necessary to develop a preprocessing method that is independent of a dataset, to apply gene expression data to the prediction model.

Our PIK3CA prediction model was similar to the RAS activation prediction model in terms of AUROC (0.84). However the AUPR of our model was lower than the RAS activation model (0.39 versus 0.63). The reason for our lower AUPR may be explained by the low prevalence rate of PIK3CA mutations, and an imbalanced dataset. The model for RAS activation trained with cancer types with more than 0.05 prevalence of RAS activation to avoid imbalance classification problem. We included all cancer types in our modeling process. The lower prevalence rate of target variables meant our dataset had a lower AUPR baseline. In the sub-analysis performance of each cancer type, the cancer types with higher PIK3CA mutation rates showed better AUPRs.

Our model included cancer types as predictors, and they were stronger predictors than gene expression. The varying prevalence of PIC3CA mutations across cancer types may be a reason for the strong predictive power of cancer types. If the cancer type was wrong or could not be determined, our model performance was poor.

Some significant gene expression predictors were closely related to PTEN and the PI3K pathway. PTEN and IGFR1R were the strongest gene expression predictors, which has negative and positive predictive powers. IGF1R is a tyrosine kinase receptor that activates PI3K [13], and PTEN is an important regulator of PIP3 by dephosphorylating PIP3, in contrast to PI3K [7].

Several studies have attempted to predict genomic alterations from gene expression data [4, 14]. A study investigated PIK3CA mutation predictions using gene-expression signatures which is a sum of the average of the logarithmic gene expression. The model showed good performance AUROC 0.71 in an independent test set [4, 14]. Another study predicted copy number alterations with gene expression, using a multinomial logistic regression model with least absolute shrinkage and selection operator (LASSO) parameters [15]. The prediction of the 1p/19q codel was very good, with an AUROC of 0.997, and gene-level predictions were good, with an AUROC of 0.75 [15]. A Hidden Markov Model Approach for Prediction of Genomic Alterations from Gene Expression Profiling [16]. A logistic regression model was used for MYCN gene amplification in neuroblastoma [17].

Our study suggested that the prediction of genomic alterations using gene expression data was possible, with good performance. However, improved performances are required for clinical tests, and the standardization of generation processing of gene expression data is also needed.

# Figure legends

**Figure 1.** Prevalence rate of PIK3CA mutations across cancer types. Cancer type abbreviations are explained in the S1 Appendix.

**Figure 2**. Summary of modeling results. (A) Left: receiver operating characteristic (ROC) curve. Right: precision-recall (PR) curve of train-set and test-set. The horizontal green line is the PIK3CA mutation rate (0.11) (B) Correlation between train-set and test-set of the area under the receiver operating characteristic curve (AUROC), and the area under the precision-recall curve (AUPR) among cancer types. The gray band is the 95% confidence interval. Abbreviations are explained in the S1 Appendix. (C) Correlations between the PIK3CA mutation rate of the AUROC, and the AUPR.

**Figure 3**. Coefficient model. (A) Top 30 high mRNA coefficients. (B) Cancer type coefficients. Cancer types abbreviations are explained in the S1 Appendix.

# Supporting information

S1 Appendix.

# References

1. Dercle L, Fronheiser M, Lu L, Du S, Hayes W, Leung DK, et al. Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics. Clin Cancer Res. 2020;26: 2151-2162. doi:[10.1158/1078-0432.CCR-19-2942](https://doi.org/10.1158/1078-0432.CCR-19-2942).
2. Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyö D, et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018;24: 1559-1567. doi:[10.1038/s41591-018-0177-5](https://doi.org/10.1038/s41591-018-0177-5).
3. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, et al. Machine learning detects pan-cancer Ras pathway activation in the cancer genome atlas. Cell Rep. 2018;23: 172-180.e3. doi:[10.1016/j.celrep.2018.03.046](https://doi.org/10.1016/j.celrep.2018.03.046).
4. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor positive breast cancer. PNAS. 2010;107: 10208-10213. doi:[10.1073/pnas.0907011107](https://doi.org/10.1073/pnas.0907011107).
5. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, et al. Machine learning detects pan-cancer Ras pathway activation in the cancer genome atlas. Cell Rep. 2018;23: 172-180.e3. doi:10.1016/j.celrep.2018.03.046.
6. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor positive advanced breast cancer. 2019;380: 1929-1940. doi:10.1056/NEJMoa1813904.
7. Cantley LC. The phosphoinositide 3-kinase pathway. AAAS. 2002;296: 1655-1657. doi:10.1126/science.296.5573.1655.
8. Jacobsen A, Luna A. Cgdsr: R-based API for accessing the MSKCC cancer genomics data server (CGDS). 2019
9. Kuhn M, Wickham H. Recipes: preprocessing tools to create design matrices. 2020
10. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33: 1-22
11. Saito T, Rehmsmeier M. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLOS ONE. 10:e0118432. doi:10.1371/journal.pone.0118432.
12. Kuhn M, Wickham H. Tidymodels: easily install and load the ’tidymodels’ packages. 2020.
13. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195: 127-137. doi:10.1016/S0304-3835(03)00159-9.
14. Cizkova M, Cizeron-Clairac G, Vacher S, Susini A, Andrieu C, Lidereau R, et al. Gene expression profiling reveals new aspects of PIK3CA mutation in ER alpha-positive breast cancer: major implication of the Wnt signaling pathway. PLOS ONE. 5:e15647. doi:10.1371/journal.pone.0015647.
15. Mu Q, Wang J. CNAPE: a machine learning method for copy number alteration prediction from gene expression. IEEE/ACM T Comput Bi. 2019; 1-1. doi:10.1109/TCBB.2019.2944827.
16. Mu Q, Wang J. CNAPE: a machine learning method for copy number alteration prediction from gene expression. IEEE/ACM T Comput Bi. 2019; 1-1. doi:10.1109/TCBB.2019.2944827.
17. Geng H, Ali HH, Chan WC. A hidden Markov model approach for prediction of genomic alterations from gene expression profiling. In: Măndoiu I, Sunderraman R, Zelikovsky A, editors. Bioinformatics Research and Applications. Berlin, Heidelberg: Springer; 2008. pp. 414-425. doi:10.1007/978-3-540-79450-9\_38.
18. He X, Qin C, Zhao Y, Zou L, Zhao H, Cheng C. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma. Cancer Commun. 2020;40: 105-118. doi:10.1002/cac2.12016.